David Shotlander retweeted
Oh hey there @BrendanCarrFCC this appears to be you?
David Shotlander retweeted
On Aug 22, Partner David Shotlander will present for @KnowGroupCLECPE
His session is "Balancing Competition and Innovation Amid the Changing Antitrust Landscape".
For more, see here: knowledgewebcasts.com/know-p…
David Shotlander retweeted
👕 RT for a chance to win 👕
Retweet this post and follow us and @MetsTeamStore for your chance to win a @JustinVerlander t-shirt.
David Shotlander retweeted
We're honored to receive the Compass Award from @LCLD_rgrey in recognition of activities promoting diversity in the legal profession.
haugpartners.com/article/hau…
David Shotlander retweeted
🎺 RT TO WIN 🎺
Retweet this for a chance to win a baseball signed by @SugarDiaz39!
David Shotlander retweeted
To celebrate the #Mets signing a couple of All-Stars we’re giving away these two cards to one lucky winner!
Retweet and follow to enter.
David Shotlander retweeted
The ultimate #Mets gameday experience could be yours!
Enter for the chance to win here 👉 atmlb.com/3BMpQA6
David Shotlander retweeted
In @foodanddruglaw Update Magazine’s Fall 2022 issue, David Shotlander & Tiffany Jang explain a new US Senate bill & a FTC 6(b) study aimed at curbing controversial PBM practices & promoting transparency in the pharmaceutical industry.
fdli.org/2022/09/senate-bill…
#PBM
David Shotlander retweeted
Today, TKG will present its "Navigating Antitrust Issues in the Pharmaceutical and Life Science Industries: Key Trends and Challenges Explored" webcast. David Shotlander is a keynote speaker for this program.
knowledgewebcasts.com/know-p…
#antitrust #lifesciences #pharma #CLE
David Shotlander retweeted
⚾️ RT TO WIN ⚾️
Retweet this for a chance to win a @tai_walker autographed baseball. #LGM
David Shotlander retweeted
How does anyone read the legislative history of the Sherman Act, and conclude that the statutory language was clear to that Congress and understood not to require interpretation by the courts on a case-by-case basis?
David Shotlander retweeted
A recent 9th Circuit decision could open the door for massive class actions and create a circuit-split.: David Shotlander and Ralph E. Labaton discuss this update.
haugpartners.com/article/en-…
#Antitrust #NinthCircuit
David Shotlander retweeted
"#FTC’s Pharmaceutical #Antitrust Suit Over Opioid License Agreement Between Endo and Impax Dismissed Because #Patent Act Permits Exclusive Licenses" by David Shotlander and Ralph E. Labaton:
haugpartners.com/article/ftc…
David Shotlander retweeted
In DBN Holding, Inc. v. ITC, the #CourtofAppeals for the #FederalCircuit upheld a $6.2M civil penalty levied against DBN for violating a remedial consent order, had been invalidated - Jonathan Herstoff and Christopher Gosselin analyze further.
haugpartners.com/article/tim…
David Shotlander retweeted
"Federal Circuit Denies Rehearing in #Biogen v. #Mylan: Dissent Raises Four Written Description “Points of Error” That En Banc Court Should Have Corrected" by Robert Colletti and Tiffany Jang:
haugpartners.com/article/fed…
#federalcircuit #patent
David Shotlander retweeted
A federal court reinstated an #antitrust law that applies a more restrictive standard & individual liability to potentially #anticompetitive pharmaceutical “#settlement agreements negotiated, completed, or entered into within California’s borders.":
haugpartners.com/article/cal…
David Shotlander retweeted
Haug Partners LLP is pleased to announce that it has joined the Leadership Council on Legal Diversity (LCLD):
businesswire.com/news/home/2…
@LCLD_rgrey #LCLD #Legal #Diversity
David Shotlander retweeted
Haug Partners LLP Ranked in the 2022 Edition of U.S. News - Best Lawyers' "Best Law Firms"
haugpartners.com/article/hau…
@BestLawyers #BestLawyers #Law #NYC #Boston #DC #Patent #Antitrust #FDA
David Shotlander retweeted
"The Sham Litigation Exception after AbbVie - Is the Subjective Element a Sham?" by Nisha Gera and David Shotlander:
haugpartners.com/article/the…
#AbbVie #Sham #Litigation #FTC
David Shotlander retweeted
David Shotlander & Tiffany Jang break down @US_FDA Acting Commissioner’s September 10 letter to the @uspto, which raised several of FDA’s concerns relating to patents and competition in the pharmaceutical marketplace.
haugpartners.com/article/fda…
#FDA #USPTO #Patent #Pharmaceutical

























